David J. Mauro - 09 Feb 2024 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Signature
/s/ Jonathan Golightly, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
09 Feb 2024
Net transactions value
-$19,090
Form type
4
Filing time
13 Feb 2024, 19:03:37 UTC
Previous filing
07 Jun 2023
Next filing
17 May 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Award $0 +6,040 +3.2% $0.000000 196,753 09 Feb 2024 Direct F1
transaction RXRX Class A Common Stock Award $0 +49,768 +25% $0.000000 246,521 09 Feb 2024 Direct F2
transaction RXRX Class A Common Stock Tax liability $19,090 -1,892 -0.77% $10.09 244,629 09 Feb 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (RIght to Buy) Award $0 +99,537 $0.000000 99,537 09 Feb 2024 Class A Common Stock 99,537 $10.09 Direct F5
holding RXRX Stock Option (Right to Buy) 381,426 09 Feb 2024 Class A Common Stock 381,426 $8.77 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This RSU vested immediately upon the grant date.
F2 This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2024 and every three months thereafter.
F3 Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F4 This option vests as to one fourth (1/4th) of the shares subject to the option on June 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter subject to Reporting Person's continued service to the Issuer through each such vesting date.
F5 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.